

## Effect of the dietary delivery matrix on vitamin D<sub>3</sub> bioavailability and bone mineralisation in vitamin-D<sub>3</sub>-deficient growing male rats

Alison J. Hodgkinson<sup>1\*</sup>, Olivia A. M. Wallace<sup>1</sup>, Marlena C. Kruger<sup>2</sup> and Colin G. Prosser<sup>3</sup>

<sup>1</sup>Food and Bio-based Products, AgResearch Limited, PB 3123, Hamilton 3240, New Zealand

<sup>2</sup>School of Food and Nutrition, Massey University Manawatu, PB 11 222, Palmerston North 4442, New Zealand

<sup>3</sup>Dairy Goat Co-operative (NZ) Limited, 18 Gallagher Drive, Hamilton 3206, New Zealand

(Submitted 16 May 2017 – Final revision received 24 July 2017 – Accepted 25 August 2017 – First published online 22 December 2017)

### Abstract

This study assessed bioavailability and utilisation of vitamin D<sub>3</sub> in two feeding trials using young, growing Sprague–Dawley male rats. Trial one fed animals standard AIN-93G diet (casein protein) containing no vitamin D<sub>3</sub> and goat or cow skimmed milk supplemented with vitamin D<sub>3</sub>. Trial two fed animals modified dairy-free AIN-93G diet (egg albumin) containing no vitamin D<sub>3</sub> and goat or cow skimmed or full-fat milk supplemented with vitamin D<sub>3</sub>. Control groups received AIN-93G diets with or without vitamin D, and water. At 8 weeks of age, blood samples were collected for vitamin and mineral analysis, and femurs and spines were collected for assessment of bone mineralisation and strength. In both trials, analyses showed differences in bioavailability of vitamin D<sub>3</sub>, with ratios of serum 25-hydroxyvitamin D<sub>3</sub> to vitamin D<sub>3</sub> intake more than 2-fold higher in groups drinking supplemented milk compared with groups fed supplemented solid food. Bone mineralisation was higher in groups drinking supplemented milk compared with groups fed supplemented solid food, for both trials ( $P < 0.05$ ). There was no difference in the parameters tested between skimmed milk and full-fat milk or between cow milk and goat milk. Comparison of the two trials suggested that dietary protein source promoted bone mineralisation in a growing rat model: modified AIN-93G with egg albumin produced lower bone mineralisation compared with standard AIN-93G with casein. Overall, this study showed that effects of vitamin D<sub>3</sub> deficiency in solid diets were reversed by offering milk supplemented with vitamin D<sub>3</sub>, and suggests that using milk as a vehicle to deliver vitamin D is advantageous.

**Key words:** Milk: Vitamin D<sub>3</sub>: Vitamin D deficiency: Vitamin D bioavailability: Bone mineralisation

Vitamin D plays a critical role in bone mineralisation during growth phases of infancy and childhood. Recent population studies report a high prevalence of vitamin D deficiency and insufficiency, with suggested contributing factors being avoidance of sun exposure owing to skin cancer risks, increased indoor activities and changes in dietary habits<sup>(1)</sup>. Natural dietary sources of vitamin D<sub>3</sub> are limited and include oil-rich fish and eggs; therefore, vitamin D<sub>3</sub> levels are largely dependent on sunlight exposure<sup>(2)</sup>. Supplemented foods may provide a further source of vitamin D. Vitamin D<sub>3</sub> (animal sourced) and vitamin D<sub>2</sub> (plant sourced) have both been used in dietary fortification and as supplements, although recent studies suggest that vitamin D<sub>3</sub> is more readily utilised by humans<sup>(3)</sup>.

Both forms of vitamin D are metabolised by hepatic 25-hydroxylase into 25-hydroxyvitamin D (25(OH)D). This biologically inactive form of vitamin D is further modified by renal 1 $\alpha$ -hydroxylase into the active metabolite 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D). The activity of 1,25(OH)<sub>2</sub>D<sub>3</sub> is via binding to its receptor, which is highly conserved across mammalian species<sup>(4)</sup>. Although produced in the kidney,

1,25(OH)<sub>2</sub>D acts in intestinal cells to increase Ca and P absorption or in the bone to stimulate differentiation and activation of bone cells<sup>(5,6)</sup>. Owing to its longer half-life, compared with 1,25(OH)<sub>2</sub>D, serum levels of 25(OH)D are considered the best indicator of vitamin D status<sup>(6,7)</sup>.

Milk provides an ideal vehicle for supplementing vitamin D<sup>(6,8)</sup>, with this being practised voluntarily in some European countries<sup>(9)</sup> and mandatorily in North America<sup>(10)</sup>. Milk products come with normal or reduced fat content and from different animal sources, although cow milk products are predominant<sup>(11)</sup>. With increasing world-wide obesity, there is a trend for use of low-fat milk consumption for young children<sup>(12,13)</sup>. However, a cross-sectional analysis of children aged 12–72 months found a positive association between milk-fat percentage and 25(OH)D<sup>(14,15)</sup>. These authors concluded that low-fat milk (1 or 2%) may compromise serum 25(OH)D levels and hence bone health.

To understand the effects of dietary components on bone development in humans, many researchers have used young, growing rats as a model; for example, assessment of minerals<sup>(16–18)</sup>

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; CSM, cow skimmed milk; DEXA, dual-energy X-ray absorptiometry; GSM, goat skimmed milk.

\* **Corresponding author:** A. J. Hodgkinson, fax +64 7 838 5611, email ali.hodgkinson@agresearch.co.nz

and fatty acids<sup>(19)</sup>. Young growing rats have also been used to study the effects of vitamin D on bone development<sup>(20,21)</sup>. Rats metabolise this vitamin using the same metabolic pathways as humans<sup>(20)</sup>, and deficiencies of dietary vitamin D induce similar changes to bone strength and structure<sup>(22,23)</sup>. Therefore, this provided a suitable model for our study. We evaluated the bioavailability of vitamin D<sub>3</sub> when it was offered to young, growing male rats either in solid food or in liquid full-fat or reduced-fat milk from cows or goats, and further assessed the utilisation of this vitamin for bone mineralisation.

## Methods

### Animals

All animal experiments were performed in accordance with the guidelines of the New Zealand National Animal Ethics Advisory Committee for the use of animals in research, testing, and teaching. All experimental procedures were approved by the Ruakura Animal Ethics Committee. Sprague–Dawley male rats used in the study were housed in large cages (*n* 4/cage) under specific pathogen-free conditions, in a temperature-controlled room with a 12-h on/off light cycle.

### Feeding trials

Two feeding trials were undertaken to assess vitamin D<sub>3</sub> uptake from milk and its utilisation. In the first trial, animals were offered vitamin D supplemented in goat or cow liquid skimmed milk, while being fed a rodent diet (containing milk protein) with no vitamin D. In the second feeding trial, animals were offered vitamin D supplemented in goat or cow liquid skimmed milk or full-fat milk, while being fed a dairy-free rodent diet with no vitamin D.

### Trial 1 – diets and experimental protocols

During the study, Groups 1–4 were fed a semi-synthetic diet (standard AIN-93G Rodent Diet using milk casein as the protein source; Research Diets, Inc.; 18% protein, 65% carbohydrate; 7% fat) either containing vitamin D<sub>3</sub> (25 µg/kg) or no added vitamin D<sub>3</sub>. Group 5 was fed a dairy-free Teklad Rodent Diet (Teklad Global 18% Protein Rodent Diet; Harlan Laboratories; 18% protein; 44% carbohydrate, 6% fat) containing vitamin D<sub>3</sub> (37.5 µg/kg). Liquids (water, goat skimmed milk (GSM) and cow skimmed milk (CSM)) were supplied via drink bottles to the rats *ad libitum*. Milk was prepared fresh daily using milk powders supplied by Dairy Goat Co-operative (NZ) Ltd (DGC), with each powder reconstituted to obtain 2.4% protein, 3% carbohydrate and 1% fat. Vitamin D<sub>3</sub> (Dry vitamin D<sub>3</sub>, 100 SD/S; DSM Nutritional Products) had been added to the milk powders to give a final concentration of 8.13 µg/l in the prepared milk.

At weaning (3 weeks of age, Day 0), 40 rats were randomly allocated to five groups (*n* 8/group). Groups 1–4 were fed *ad libitum* for 1 week on standard AIN-93G Rodent Diet containing no vitamin D<sub>3</sub>. From 4 to 8 weeks of age (Days 7–35), the control group (Group 1) was fed standard AIN-93G diet containing vitamin D<sub>3</sub>, plus water. Over the same time interval, Groups 2, 3 and 4 were retained on the standard AIN-93G diet

containing no vitamin D<sub>3</sub> and were further supplemented with either water (Group 2), GSM (Group 3) or CSM (Group 4). A dairy-free control group (Group 5) was fed Teklad Rodent Diet containing vitamin D<sub>3</sub>, plus water, from weaning to 8 weeks of age.

### Trial 2 – diets and experimental protocols

During the study, all rats were fed a semi-synthetic, dairy-free diet (modified AIN-93G Rodent Diet using egg albumin as protein source; Research Diets; 18% protein, 65% carbohydrate; 7% fat; 1% Biotin) either containing vitamin D<sub>3</sub> (25.0 µg/kg) or no added vitamin D<sub>3</sub>. Liquids (water, GSM, goat full-fat milk (GWM), CSM and CWM) were supplied via drink bottles to the rats *ad libitum*. Milk was prepared fresh daily using milk powders (DGC), with each powder reconstituted to obtain the 2.4% protein and 8.13 µg/l vitamin D<sub>3</sub>. The prepared skimmed milk contained 1% milk fat and WM contained 2.6% milk fat.

At weaning (3 weeks of age, Day 0), 48 rats were randomly allocated to six groups (*n* 8 per group) and fed *ad libitum* for 1 week on modified AIN-93G diet containing no vitamin D<sub>3</sub>. From 4 to 8 weeks of age (Days 7–35), the control group (Group 1) was fed modified AIN-93G diet containing vitamin D<sub>3</sub>, plus water. Over the same time interval, the five treatment groups were retained on the modified AIN-93G diet containing no vitamin D<sub>3</sub> and were further supplemented with either water (Group 2), GSM (Group 3), GWM (Group 4), CSM (Group 5) or CWM (Group 6).

### Food monitoring and sample collection

Liquid intake (24 h) was measured when bottle contents were changed daily. During the last week of each trial, the intake of solid diet was measured daily. Samples of all solid and liquid diets were retained for compositional analysis. Rats were weighed weekly to monitor health. At 8 weeks of age, the rats were euthanised by CO<sub>2</sub> asphyxiation and cervical dislocation. Blood (6 ml) was obtained by cardiac puncture; 1 ml was allowed to clot and then centrifuged for 10 min, 1650 *g*, at room temperature. Serum was collected and stored at –20°C until analysed for minerals. The remaining blood was treated with EDTA and then centrifuged for 10 min, 1650 *g*, at room temperature. Plasma was collected and stored at –20°C until analysed for 25(OH)D<sub>3</sub>. The lumbar spine and femurs were removed by simple dissection. The left femur was scraped clean of adhering flesh. All samples were then stored in PBS solution at –20°C.

### Measurement of vitamins and minerals in diets, serum and plasma

The vitamin D<sub>3</sub> content in the solid and liquid diets was measured by AsureQuality using methods based on Brubacher *et al.* and Indyk & Woollard<sup>(24,25)</sup>. The levels of 25(OH)D<sub>3</sub> in rat plasma samples were measured by liquid chromatography-tandem MS using the method of Lankes *et al.*<sup>(26)</sup>. Ca, Mg and P levels were measured in the solid and liquid diets and in the rat sera by AsureQuality using inductively coupled plasma optical emission spectroscopy methodology.



### Dual-energy X-ray absorptiometry scans of the right femur and spine

Right femurs and spines were assessed for bone mineralisation using dual-energy X-ray absorptiometry (DEXA) measurements with a Hologic Discovery A bone densitometer. A quality control scan was undertaken at the start and end of each scanning session using a spine phantom according to the manufacturer's guidelines to verify system calibration. Before DEXA scanning, frozen right femurs and spines were thawed and dissected to a tissue depth of approximately 5 mm. Femurs and lumbar spine (LS1–LS4) were then individually scanned using a small-animal regional high-resolution protocol.

### Biomechanical properties of the femur

Before biomechanical testing, the left femurs were thawed and then held at 23°C during the tests. The femur length was measured using an electronic caliper and the wet weight recorded. The midpoint of the femur was marked with a waterproof pen and then placed in a testing jig constructed for a three-point bending test. The distance between the supporting rods had a fixed length of 12 mm. Load was applied at a constant deformation rate of 50 mm/min. Maximum force (N), elasticity (N/mm<sup>2</sup>) and breaking energy (J) were measured using a Shimadzu Ezi-test texture analyzer. The maximum force is the load required to break the bone and is thought to reflect the mineral content, as well as the protein component of bone. Measured elasticity reflects the distance in mm by which bone can bend under the applied load without permanent deformation (stiffness). Breaking energy (J) is an integration value of force (area under the force/displacement curve) that is required to fracture the bone, or can be defined as the total amount of energy bone must absorb in order to cause a break. The measured energy (J) also reflects the stiffness of bones and is thought to reflect the collagen content of bone.


### Statistical analysis

Sample size calculations of eight animals per group were based on femur bone area, with an estimated difference of 0.3 (cm<sup>2</sup>), an SD of 0.09 (cm<sup>2</sup>), power of 80% and significance of 5%. Data for water and liquid consumption are presented as means with their standard errors. Measurements of weight gain, vitamin D and mineral levels in blood, DEXA and bone biomechanics were analysed by treatment using ANCOVA in Genstat (Genstat for Windows 17th edition; VSN International). Analysis for weights used Day 0 (start of trial at weaning, animals 3 weeks old) weight as a covariate. Analysis for DEXA and bone biomechanics used animal weight at end of trial (Day 34 weight) as a covariate. Means of treatment groups are reported with their corresponding standard errors of difference. Means were compared using Fisher's unprotected least significant difference test and *P* values <0.05 were considered significant.

## Results

### Trial 1

**Animal weight gain over the trial.** All animals showed a steady weight gain over the course of the trial (Fig. 1). By Day 7,



**Fig. 1.** Trial 1 – mean weight gain over 5 weeks of feeding. At day 0, Groups 1, 2, 3 and 4 were fed standard AIN-93G diet with no vitamin D<sub>3</sub>, plus water. From days 7 to 35, Group 1 was fed standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 were retained on standard AIN-93G diet with no vitamin D<sub>3</sub>. Supplementary feeding with milk containing vitamin D<sub>3</sub> began at day 7 (→): Group 3 with goat skimmed milk and Group 4 with cow skimmed milk. Over this time interval, Groups 1 and 2 received water. Group 5 received Teklad diet with vitamin D<sub>3</sub> plus water throughout the trial period. Values are group means. —, Group 1 – water + D<sub>3</sub>; - - -, group 2 – water – D<sub>3</sub>; ·····, group 3 – goat skimmed + D<sub>3</sub>; ·····, group 4 – cow skimmed + D<sub>3</sub>; - - - - , group 5 – Teklad + D<sub>3</sub>.

there were no differences between Groups 1, 2, 3 and 4 (standard AIN-93G diet); however, Group 5 (Teklad diet) was heavier (*P* < 0.05) and remained the heaviest group over the remainder of the trial. From Day 10, Groups 1, 3 and 4 were heavier compared with Group 2 (standard AIN-93G with no vitamin D<sub>3</sub>, plus water; *P* < 0.05). From Day 28, Group 1 (standard AIN-93G with vitamin D<sub>3</sub>, plus water) was heavier compared with Group 4 (standard AIN-93G with no vitamin D<sub>3</sub>, plus CSM; *P* < 0.05), whereas Groups 1 and 3 were a similar weight to Group 5 (*P* < 0.05). There were no significant weight differences between Groups 1 and 3 at any of the time points measured, whereas Group 3 (GSM) tended to be heavier compared with Group 4 (CSM).

**Liquid and solid diet intake.** Over the course of the trial, rats consumed increasing volumes of liquid (Table 1). Rats drinking water consumed a smaller volume compared with rats drinking milk. Group 1 drank less water compared with Groups 2 and 5. Rats drinking CSM drank less volume compared with rats drinking GSM. In the final week of feeding, solid food intake (Table 1) was higher in Group 5 (Teklad diet with vitamin D<sub>3</sub>), followed by Group 1 (standard AIN-93G with vitamin D<sub>3</sub>). Groups 2, 3 and 4 had similar solid food intakes. In the fourth week of supplementary feeding, the vitamin D<sub>3</sub> intake from solid food for Groups 1 and 5 was estimated to be 0.94 and

**Table 1.** Trial 1 – group daily intake of liquid over 4 weeks of supplementary feeding and solid diet intake in week 4\* (Mean intake per group per d for each week, with their standard errors)

Weeks	Group 1		Group 2		Group 3		Group 4		Group 5	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Liquid diet intake (ml)										
Water                      Water                      GSM                      CSM                      Water										
1	68.5	0.9	106.4	5.8	169.3	5.6	130.9	3.7	89.5	2.9
2	76.1	1.5	116.8	3.9	188.7	11.1	131.2	5.7	108.0	1.8
3	84.9	2.7	123.5	2.2	205.7	6.4	123.2	16.6	119.1	2.2
4	86.5	2.0	117.7	2.7	211.3	5.0	144.6	7.4	120.2	2.6
Solid diet intake (g)										
Std AIN-93G with vitamin D <sub>3</sub> Std AIN-93G with no vitamin D <sub>3</sub> Teklad diet with vitamin D <sub>3</sub>										
Mean                      SEM                      Mean                      SEM                      Mean                      SEM                      Mean                      SEM                      Mean                      SEM										
4	93.6	1.3	86.8	0.5	84.8	0.8	87.4	1.1	110.6	1.4

GSM, goat skimmed milk; CSM, cow skimmed milk.

\* Group 1 received standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 received standard AIN-93G diet with no vitamin D<sub>3</sub>. Group 5 received Teklad diet with vitamin D<sub>3</sub>. Groups 1, 2 and 5 received water. Groups 3 and 4 received GSM and CSM, respectively, both containing vitamin D<sub>3</sub>.

1.15 µg/rat per d, respectively. In the final week, the vitamin D<sub>3</sub> intake from GSM (Group 3) and CSM (Group 4) was estimated to be 0.42, and 0.26 µg/rat per d, respectively.

**25-Hydroxyvitamin D levels in plasma.** Group 2 (standard AIN-93G with no vitamin D<sub>3</sub>, plus water) had very low 25(OH)D<sub>3</sub> levels (Table 2), with five of eight samples below the limits of detection. Group 1 (standard AIN-93G with vitamin D<sub>3</sub>, plus water) and Group 5 (Teklad diet with vitamin D<sub>3</sub>, plus water) had higher levels of 25(OH)D<sub>3</sub> compared with milk-fed groups, although the difference between Group 1 and Group 3 (AIN-93G with no vitamin D<sub>3</sub>, plus GSM) was not significant. Levels of 25(OH)D<sub>3</sub> in milk-fed groups were similar. The ratio of the plasma 25(OH)D<sub>3</sub> level:dietary vitamin D<sub>3</sub> intake was calculated; values for Group 1 and Group 5 were similar (0.89 and 0.78, respectively) and these values were less than half the values of the milk-fed groups. The group fed CSM had a higher ratio value compared with the GSM group (2.45 and 1.70, respectively), reflecting the average milk intake for the two groups over the trial period (33.0 ml/d per rat for the CSM group and 48.5 ml/d per rat for the GSM group).

**Minerals levels in serum.** Serum Ca levels were higher in Groups 2 and 4 compared with Groups 1, 3 and 5 (Table 2; *P*<0.05). Mg and P levels were higher in Groups 1, 3 and 5 compared with Groups 2 and 4 (Table 2: *P*<0.05). Phosphate levels were also higher in Groups 1, 3 and 5 compared with Groups 2 and 4 (Table 2), with Group 5 having the highest levels. Phosphate levels were not significantly different between milk-fed groups.

**Dual-energy X-ray absorptiometry of right femur and spine.**


The BMC and BMD were determined for the right femur and lumbar spine collected from animals at the end of Trial 1 (Fig. 2 and 3, respectively, adjusted for rat weight at end

**Table 2.** Trial 1 – 25-hydroxyvitamin D<sub>3</sub> (25(OH)D<sub>3</sub>) was measured in plasma and minerals were measured in sera collected from rats at the end of the 4-week supplementary feeding period\* (Group means with their standard error of difference (SED))


Groups	25(OH)D <sub>3</sub> (nmol/l)	Ca (mmol/l)	Mg (mmol/l)	P (mmol/l)
1	33.6 <sup>a,b</sup>	3.06 <sup>a</sup>	1.39 <sup>a</sup>	1.49 <sup>a,b</sup>
2	1.1 <sup>c</sup>	3.36 <sup>b</sup>	1.12 <sup>b</sup>	1.24 <sup>c</sup>
3	28.6 <sup>a,d</sup>	3.12 <sup>a</sup>	1.39 <sup>a</sup>	1.40 <sup>a,d</sup>
4	25.6 <sup>d</sup>	3.31 <sup>b</sup>	1.13 <sup>b</sup>	1.35 <sup>c,d</sup>
5	36.0 <sup>b</sup>	3.08 <sup>a</sup>	1.52 <sup>a</sup>	1.61 <sup>b</sup>
SED	2.5	0.05	0.07	0.06

<sup>a,b,c,d</sup> Mean values within a column with unlike superscript letters are significantly different (ANOVA, *P*<0.05).

\* Over this time, Group 1 received standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 received standard AIN-93G diet with no vitamin D<sub>3</sub>. Group 5 received Teklad diet with vitamin D<sub>3</sub>. Groups 1, 2 and 5 received water. Groups 3 and 4 received goat skimmed milk and cow skimmed milk, respectively, both containing vitamin D<sub>3</sub>.



**Fig. 2.** Trial 1 – bone mineral content (BMC; adjusted for animal weight at end of trial) of right femur (A) and lumbar spine (B) collected at the end of the 4-week supplementary feeding. Over this time, Group 1 received standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 received standard AIN-93G diet with no vitamin D<sub>3</sub>. Group 5 received Teklad diet with vitamin D<sub>3</sub>. Groups 1, 2 and 5 received water. Groups 3 and 4 received goat skimmed milk and cow skimmed milk, respectively, both containing vitamin D<sub>3</sub>. Values are group means with their standard error of difference (SED). <sup>a,b</sup> Mean values with unlike letters are significantly different (ANOVA, *P*<0.05).



**Fig. 3.** Trial 1 – bone mineral density (BMD; adjusted for animal weight at end of trial) of right femur (A) and lumbar spine (B) collected at the end of the 4-week supplementary feeding. Over this time, Group 1 received standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 received standard AIN-93G diet with no vitamin D<sub>3</sub>. Group 5 received Teklad diet with vitamin D<sub>3</sub>. Groups 1, 2 and 5 received water. Groups 3 and 4 received goat skimmed milk and cow skimmed milk, respectively, both containing vitamin D<sub>3</sub>. Values are group means with their standard error of difference (SED). <sup>a,b,c</sup> Mean values with unlike letters are significantly different (ANOVA, *P* < 0.05).

**Table 3.** Trial 1 – wet weight, length, strength and elasticity of left femur (adjusted for animal weight at end of trial) collected at the end of the 4-week supplementary feeding\* (Group means with their standard error of difference (SED))


Groups	Weight (g)	Length (mm)	Maximum load (N)	Elasticity (N/mm <sup>2</sup> )	Energy (J)
1	1.014 <sup>a,b</sup>	34.27 <sup>a</sup>	105.8 <sup>a,b</sup>	347.3 <sup>b</sup>	0.143 <sup>a,b</sup>
2	1.057 <sup>b</sup>	34.27 <sup>a</sup>	95.5 <sup>a</sup>	242.5 <sup>a</sup>	0.170 <sup>b</sup>
3	1.002 <sup>a,b</sup>	34.62 <sup>a</sup>	108.7 <sup>b</sup>	388.1 <sup>b</sup>	0.133 <sup>a</sup>
4	1.026 <sup>b</sup>	34.56 <sup>a</sup>	109.0 <sup>b</sup>	346.8 <sup>b</sup>	0.143 <sup>a,b</sup>
5	0.960 <sup>a</sup>	34.80 <sup>a</sup>	102.6 <sup>a,b</sup>	389.2 <sup>b</sup>	0.114 <sup>a</sup>
SED	0.029	0.438	6.070	44.70	0.017

<sup>a,b</sup> Mean values within a column with unlike superscript letters are significantly different (ANOVA, *P* < 0.05)

\* Over this time, Group 1 received standard AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3 and 4 received standard AIN-93G diet with no vitamin D<sub>3</sub>. Group 5 received Teklad diet with vitamin D<sub>3</sub>. Groups 1, 2 and 5 received water. Groups 3 and 4 received goat skimmed milk and cow skimmed milk, respectively, both containing vitamin D<sub>3</sub>.

of trial). The BMC values for Groups 1 and 2 were similar, although the lumbar spine BMD value for Group 1 was higher compared with Group 2 (*P* < 0.05). The milk-fed groups and Group 5 (Teklad diet with vitamin D<sub>3</sub>, plus water) had similar BMC values for both the right femur and lumbar spine, and these values were higher compared with Groups 1 and 2 (*P* < 0.05). Similarly, BMD values were higher for the milk-fed groups and Group 5 for both the right femur and lumbar spine compared with Groups 1 and 2 (*P* < 0.05). The BMD value for the right femur was higher in Group 5 compared with the milk-fed groups, whereas the BMD values for the spine were similar for all three of these groups.

**Bone size and strength.** Table 3 shows the biomechanical information for the left femur collected from animals at the end of Trial 1 (adjusted for rat weight at end of trial). The bone lengths for the different groups were not significantly different. Bones from rats in Group 2 could withstand less load (Max N) and fractured at a significantly lower load compared with the milk-fed Groups 3 and 4. Although the Max N value for Group 2 was also lower compared with Groups 1 and 5, values were not significantly different. The stiffness of bones was greater for



**Fig. 4.** Trial 2 – mean weight gain over 5 weeks of feeding. At day 0, all rats were fed modified AIN-93G diet containing no vitamin D<sub>3</sub>, plus water. From days 7 to 35, Group 1 was fed modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 were retained on modified AIN-93G diet with no vitamin D<sub>3</sub>. Supplementary feeding with milk containing vitamin D<sub>3</sub> began at day 7 (→): Group 3 with goat skimmed milk, Group 4 with goat full-fat milk, Group 5 with cow skimmed milk and Group 6 with cow full-fat milk. Over this time interval, Groups 1 and 2 received water. Values are group means. —, Group 1 – water + D<sub>3</sub>; - - -, group 2 – water – D<sub>3</sub>; ·····, group 3 – goat skimmed + D<sub>3</sub>; - · - ·, group 4 – goat full-fat + D<sub>3</sub>; - - - -, group 5 – cow skimmed + D<sub>3</sub>; - - - - -, group 6 – cow full-fat + D<sub>3</sub>.

other groups compared with those from Group 2, which were elastic and deforming permanently. The values for energy (J) showed that Group 2 bones were softer and absorbed more energy before cracking/fracture compared with bones from the other groups. Although energy values for Groups 1, 3, 4 and 5 were all lower than Group 2, only the mean values for Group 3 (GSM) and 5 (Teklad diet) were significantly lower (*P* < 0.05).

**Trial 2**

**Animal weight gain over the trial.** All animals showed a steady weight gain over the course of the trial (Fig. 4). By Day 7, there were no differences between groups. From Day 14, Group 1 (modified AIN-93G with vitamin D<sub>3</sub>) was heavier compared with Group 2 (modified AIN-93G with no vitamin D<sub>3</sub>) (*P* < 0.05). From Day 14, Group 3 (GSM), Group 4 (GWM) and Group 6 (CWM) were heavier compared with Groups 1 and 2 (*P* < 0.05). Group 5 (CSM) weights were similar to Group 1 and significantly lighter compared with Groups 3 (GSM) and 4 (GWM) from Day 21, but only significantly lighter compared with Group 6 (CWM) on Days 24 and 31.

**Liquid and solid diet intake.** Over the course of the trial, rats consumed increasing volumes of liquid (Table 4). Rats drinking water consumed a smaller volume compared with rats drinking milk. Rats drinking WM tended to consume less compared with

**Table 4.** Trial 2 – group daily intake of liquid over 4 weeks of supplementary feeding and solid diet intake in week 4\* (Mean intake per group per day for each week with their standard errors)

	Group 1		Group 2		Group 3		Group 4		Group 5		Group 6	
Liquid diet intake (ml)												
	Water		Water		GSM		GWM		CSM		CWM	
Weeks	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
1	71.5	4.0	62.6	2.6	113.2	5.8	87.5	3.6	82.1	5.9	87.2	3.1
2	86.1	3.5	70.3	2.5	123.8	5.0	102.5	6.2	98.9	5.3	95.5	4.7
3	100.3	3.0	83.1	2.8	180.8	11.3	112.9	3.4	119.4	15.0	110.9	3.5
4	103.4	8.3	88.3	6.0	175.6	8.0	129.8	10.6	140.3	10.9	118.1	8.1
Solid diet intake (g)												
	Mod AIN-93G with vitamin D <sub>3</sub>				Mod AIN-93G with no vitamin D <sub>3</sub>							
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
4	79.0	8.3	68.2	5.9	77.2	6.6	69.3	6.7	75.8	8.9	71.0	7.0

GSM, goat skimmed milk; GWM, goat full-fat milk; CSM, cow skimmed milk; CWM, cow full-fat milk.

\* Over this time, Group 1 received modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 received modified AIN-93G diet with no vitamin D<sub>3</sub>. Groups 1 and 2 received water. Groups 3, 4, 5 and 6 received GSM, GWM, CSM and CWM, respectively, all containing vitamin D<sub>3</sub>.

rats drinking SM. However, volumes of CSM consumed were much lower compared with volumes of GSM. In the fourth week of supplementary feeding, solid food intake (Table 4) was higher in Group 1 (modified AIN-93G with vitamin D<sub>3</sub>, plus water) and Groups 3 and 5 (modified AIN-93G with no vitamin D<sub>3</sub>, plus SM) compared with Group 2 (AIN-93G with no vitamin D<sub>3</sub>, plus water) and Groups 4 and 6 (AIN-93G with no vitamin D<sub>3</sub>, plus WM). In the 4th week of supplementary feeding, the vitamin D<sub>3</sub> intake for Group 1 was estimated to be 0.50 µg/rat per d from solid food, and 0.26, 0.25, 0.19 and 0.22 µg/rat per d from milk, for Groups 3, 4, 5 and 6, respectively.

**25-Hydroxyvitamin D levels in plasma.** Group 2 (modified AIN-93G with no vitamin D<sub>3</sub>, plus water) had very low 25(OH)D<sub>3</sub> levels (Table 5). Group 1 (modified AIN-93G with vitamin D<sub>3</sub>, plus water) had higher levels of 25(OH)D<sub>3</sub> compared with milk-fed groups ( $P < 0.01$ ). Levels of 25(OH)D<sub>3</sub> in milk-fed groups were similar. The ratio of the plasma 25(OH)D<sub>3</sub> level to dietary vitamin D<sub>3</sub> intake was calculated; the value for Group 1 (1.31) was 2- to 3-fold lower compared with the milk-fed groups. Groups 5 (CSM) and 6 (CWM) had the highest ratios (3.88 and 3.33, respectively). Values for Groups 3 (GSM) and 4 (GWM) were similar (2.78 and 2.89, respectively).

**Minerals levels in serum.** Serum Ca levels were higher in Group 1 (modified AIN-93G with vitamin D<sub>3</sub>, plus water) compared with all the other groups (Table 5;  $P < 0.05$ ), with levels for all other Groups being similar. Mg levels were also similar for all groups, with the highest Mg level in Group 4 (GWM) and the lowest in Group 1. Phosphate levels were similar in the milk-fed groups, with higher levels compared with water-fed groups. Of all the groups, Group 2 had the lowest level of phosphate ( $P < 0.05$ ).

**Dual-energy X-ray absorptiometry of right femur and spine.** The BMC and BMD for the right femur and lumbar spine

**Table 5.** Trial 2 – 25-hydroxyvitamin D<sub>3</sub> (25(OH)D<sub>3</sub>) was measured in plasma and minerals were measured in sera collected from rats at the end of the 4-week supplementary feeding period\* (Group means with their standard error of difference (SED))


Groups	25(OH)D <sub>3</sub> (nmol/l)	Ca (mmol/l)	Mg (mmol/l)	P (mmol/l)
1	34.6 <sup>c</sup>	3.18 <sup>c</sup>	1.36 <sup>a</sup>	1.29 <sup>b</sup>
2	2.3 <sup>a</sup>	2.87 <sup>a</sup>	1.43 <sup>a,b</sup>	0.97 <sup>a</sup>
3	28.6 <sup>b</sup>	2.95 <sup>a,b</sup>	1.38 <sup>a,b</sup>	1.39 <sup>b,c</sup>
4	29.1 <sup>b</sup>	2.98 <sup>b</sup>	1.49 <sup>b</sup>	1.50 <sup>c</sup>
5	29.4 <sup>b</sup>	2.96 <sup>a,b</sup>	1.47 <sup>a,b</sup>	1.42 <sup>b,c</sup>
6	28.9 <sup>b</sup>	2.93 <sup>a,b</sup>	1.40 <sup>a</sup>	1.40 <sup>b,c</sup>
SED	2.3	0.05	0.06	0.08

<sup>a,b,c</sup> Mean values within a column with unlike superscript letters are significantly different (ANOVA,  $P < 0.05$ ).


\* Over this time, Group 1 received modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 received modified AIN-93G diet with no vitamin D<sub>3</sub>. Groups 1 and 2 received water. Groups 3, 4, 5 and 6 received goat skimmed milk, goat full-fat milk, cow skimmed milk and cow full-fat milk, respectively, all containing vitamin D<sub>3</sub>.

collected from animals at the end of Trial 2 are shown in Fig. 5 and 6, respectively (adjusted for rat weight at end of trial). Group 1 (modified AIN-93G with vitamin D<sub>3</sub>) and Group 2 (modified AIN-93G with no vitamin D<sub>3</sub>) had similar BMC and BMD values except for the BMC value of the lumbar spine, which was 1.3-fold higher for Group 1 compared with Group 2 ( $P < 0.05$ ). All milk-fed groups had similar BMC and BMD values for both the right femur and lumbar spine. The exception to this was that the femur BMC value for Group 6 (CWM) was lower compared with Group 3 (GSM) and the lumbar spine BMD value for Group 5 (CSM) was lower compared with Group 6 (CWM). All BMC and BMD values for the milk-fed groups were significantly higher compared with both Groups 1 and 2, except for the lumbar spine BMC value for Group 6 (CWM), which was similar to the value for Group 1.

**Bone size and strength.** Table 6 shows the biomechanical information from the left femur collected from animals at the



**Fig. 5.** Trial 2 – bone mineral content (BMC; adjusted for animal weight at end of trial) of right femur (A) and lumbar spine (B) collected at the end of the 4-week supplementary feeding. Over this time, Group 1 received modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 received modified AIN-93G diet with no vitamin D<sub>3</sub>. Groups 1 and 2 received water. Groups 3, 4, 5 and 6 received goat skimmed milk, goat full-fat milk, cow skimmed milk and cow full-fat milk, respectively, all containing vitamin D<sub>3</sub>. Values are group means with their standard error of difference (SED). <sup>a,b,c</sup> Mean values with unlike letters are significantly different (ANOVA, *P* < 0.05).



**Fig. 6.** Trial 2 – bone mineral density (BMD; adjusted for animal weight at end of trial) of right femur (A) and lumbar spine (B) collected at the end of the 4-week supplementary feeding. Over this time, Group 1 received modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 received modified AIN-93G diet with no vitamin D<sub>3</sub>. Groups 1 and 2 received water. Groups 3, 4, 5 and 6 received goat skimmed milk, goat full-fat milk, cow skimmed milk and cow full-fat milk, respectively, all containing vitamin D<sub>3</sub>. Values are group means with their standard error of difference (SED). <sup>a,b,c</sup> Mean values with unlike letters are significantly different (ANOVA, *P* < 0.05).

**Table 6.** Trial 2 – wet weight, length, strength and elasticity of left femur (adjusted for animal weight at end of trial) collected at the end of the 4-week supplementary feeding\* (Group means with standard error of difference (SED))

Groups	Weight (g)	Length (mm)	Maximum load (N)	Elasticity (N/mm <sup>2</sup> )	Energy (J)
1	0.985 <sup>a</sup>	32.97 <sup>b</sup>	74.39 <sup>a</sup>	189.8 <sup>a</sup>	0.141 <sup>a</sup>
2	0.954 <sup>a</sup>	31.27 <sup>a</sup>	70.75 <sup>a</sup>	209.3 <sup>a</sup>	0.114 <sup>b</sup>
3	1.047 <sup>a</sup>	33.48 <sup>b</sup>	96.24 <sup>c</sup>	291.4 <sup>b</sup>	0.119 <sup>a,b</sup>
4	0.976 <sup>a</sup>	33.70 <sup>b</sup>	82.08 <sup>a,b</sup>	225.8 <sup>a,b</sup>	0.111 <sup>b</sup>
5	0.978 <sup>a</sup>	33.54 <sup>b</sup>	91.94 <sup>b,c</sup>	259.9 <sup>a,b</sup>	0.122 <sup>a,b</sup>
6	0.989 <sup>a</sup>	33.30 <sup>b</sup>	80.57 <sup>a,b</sup>	260.3 <sup>a,b</sup>	0.128 <sup>a,b</sup>
SED	0.049	0.506	6.71	38.1	0.012

<sup>a,b,c</sup> Mean values within a column with unlike superscript letters are significantly different (ANOVA, *P* < 0.05).

\* Over this time, Group 1 received modified AIN-93G diet with vitamin D<sub>3</sub>. Groups 2, 3, 4, 5 and 6 received modified AIN-93G diet with no vitamin D<sub>3</sub>. Groups 1 and 2 received water. Groups 3, 4, 5 and 6 received goat skimmed milk, goat full-fat milk, cow skimmed milk and cow full-fat milk, respectively, all containing vitamin D<sub>3</sub>.

end of Trial 2 (adjusted for animal weight at end of trial). The femurs collected from Group 2 were significantly shorter compared with all other groups. The required fracture loads (Max N) for rats in Groups 1 and 2 were similar, and significantly lower compared with bones from rats in Groups 3 (GSM) and 5 (CSM). The fracture load for the skimmed-milk-fed groups was higher compared with the full-fat-fed groups, although only Group 3 (GSM) was significantly higher. The elasticity was less for Groups 1 and 2 compared with all the milk-fed groups, reflecting lower mineralised bones for Groups 1 and 2 and consistent with the DEXA results.

### Discussion

In our study, we investigated the benefits of supplementing vitamin D in milk using a model of young growing rats with vitamin D deficiency. The animals fed insufficient vitamin D over the course of the two trials (Group 2) had very low serum 25(OH)D<sub>3</sub>, which shows that the model did result in Vitamin D deficiency. We found that circulating levels of serum 25(OH)D<sub>3</sub> were higher in groups fed vitamin D in the solid food compared with groups fed vitamin D in milk and was likely because of the higher estimated intake of vitamin D from solid food. This outcome was the same for both trials, feeding either the standard AIN-93G diet with casein as the protein source or modified AIN-93G with egg albumin as the protein source. However, although the vitamin D intake was 2- to 4-fold higher from solid food, serum 25(OH)D<sub>3</sub> levels were only 1- to 2-fold higher in those animals that consumed this food compared with animals drinking milk containing vitamin D<sub>3</sub>. This may suggest that the bioavailability of vitamin D<sub>3</sub> from milk is greater compared with incorporating the vitamin into solid food.

We found little difference in serum 25(OH)D<sub>3</sub> levels when the fat-soluble vitamin D<sub>3</sub> was supplemented into full-fat milk compared with skimmed milk, with this outcome being the same for both cow milk and goat milk (Trial 2). The response of serum 25(OH)D<sub>3</sub> levels to supplementation is reported to vary widely among individuals, and the presence of foods may influence this. Perfusion experiments in rats have demonstrated that PUFA decreased vitamin D<sub>3</sub> absorption<sup>(27)</sup>. However, in human studies, absorption of supplemental vitamin D<sub>3</sub> with either fat or non-fat meals have shown inconsistent results for improvements in serum 25(OH)D<sub>3</sub> levels<sup>(28–30)</sup>. Vanderhout *et al.* found that children consuming higher milk-fat percentage milk supplemented with vitamin D had higher vitamin 25(OH)D<sub>3</sub> levels compared with consumption of low-fat fortified milk<sup>(14,15)</sup>. Generally, studies in young children have shown improved vitamin D status with consumption of fortified milk<sup>(31,32)</sup>.

Our trial data demonstrated that offering vitamin D<sub>3</sub> in milk reversed the effects of vitamin D deficiency and increased bone mineralisation parameters, resulting in stronger more resilient bones with higher resistance to fracture. In addition, providing vitamin D<sub>3</sub> in milk improved BMC and BMD values compared with providing vitamin D in the AIN-93G diets. This observation was the same for both trials, feeding either the standard or modified AIN-93G with different sources of protein. Animals fed milk did tend to be heavier compared with water-fed animals,



with this being most apparent in Trial 2. Therefore, for bone parameter comparisons, end of trial body weight was used as a covariate based on the rationale that the weight of an animal has an impact on bone mechanics<sup>(33,34)</sup>. In this way, the changes reported were over and above those that may be attributable to weight differences.

Interestingly, animals fed the vitamin D-sufficient grain/plant protein-based rodent diet (Teklad diet) had BMC and BMD values very similar to the milk-fed groups and for these parameters also outperformed animals fed vitamin D-sufficient AIN-93G (Trial 1). On the other hand, groups fed different vitamin D-sufficient solid diets could not be differentiated by their biomechanical bone data. The Teklad diet used in Trial 1 did contain soyabean meal as an ingredient. A study has reported that soya protein prevented bone loss in an ovariectomised rat model when compared with a diet containing casein as protein<sup>(35,36)</sup>, although it was not identified whether the change was due to the protein itself or to the presence of isoflavones in the soyabean preparation. A study that directly compared casein protein and soya protein, with and without the addition of soya isoflavones, found no effects of isoflavones, at the levels tested, and no differences between protein source<sup>(37)</sup>.

Comparison of our two trials showed a marked difference in bone mineralisation for those animals fed vitamin D-sufficient AIN-93G with different protein sources (Group 1). Animals fed the standard AIN-93G containing milk casein had higher BMC and BMD values compared with animals fed modified AIN-93G containing egg albumin. Interestingly, comparison of Group 3, fed GSM with vitamin D in both trials, also showed similar effects: lower BMC and BMD values in Trial 2 using egg albumin as protein in the AIN-93G diet, compared with Trial 1, even though Group 3 also had casein provided in the milk. All in all, these results suggest that in a growing rat model dietary protein source has an effect on bone mineralisation. Casein phosphopeptides, naturally formed during enzymatic digestion of casein, have been shown to improve Ca absorption<sup>(38–40)</sup>, although bone mineralisation may not be similarly improved<sup>(41)</sup>. Further work is required to determine whether providing casein as protein in solid food improved bone mineralisation or whether egg albumin was detrimental. Egg albumin does contain avidin, which is known to have a high affinity for binding vitamin B<sub>7</sub> (biotin)<sup>(42)</sup>. However, the modified AIN-93G diet was further supplemented with 1% biotin to counter any potential effects of avidin reducing vitamin B<sub>7</sub> levels in the animals fed this diet. The modified AIN-93G was also supplemented with additional P to provide the recommended dietary intake of this mineral, similar to the level in standard AIN-93G diet where an amount of P is provided by the casein.

Our findings suggest that using milk as a vehicle to deliver vitamin D is advantageous. This was two-fold. First, there was increased uptake of vitamin D<sub>3</sub> supplied in milk compared with supplementing the vitamin in a solid food matrix. Second, those animals fed supplemented milk also had increased bone strength and resilience. While rat studies cannot be directly translated to humans, the action of vitamin D<sub>3</sub> is very similar in the two species. Human studies show that supplementation with vitamin D has proven beneficial for bone health, especially

for at-risk groups such as infants and young children<sup>(43)</sup>, as well as older people<sup>(44)</sup>. Using milk as a vehicle for vitamin D supplementation allows for improved compliance, particularly in young children for whom milk is a major food. Interestingly, we found no difference in the uptake or bioavailability of vitamin D when supplemented in skimmed milk and full-fat milk, and no difference between cow or goat milk.

Our results are limited by the aspect that the diets were fed *ad libitum*. Groups consumed different amounts of solid and liquid diet, resulting in different weight gains. However, to compensate for these differences, we used end of trial weight as a covariate, when analysing the bone data. Another limitation was the length of time the animals were maintained on the trial diets. This may not have been long enough to deplete the vitamin reserves supplied by the mother's milk because the half-life of the vitamin D metabolite 25(OH)D<sub>3</sub> is 15 d<sup>(45)</sup>. On the other hand, that Group 2 animals fed no vitamin D<sub>3</sub> had very low or undetectable blood levels of 25(OH)D<sub>3</sub> suggests that the length of trial time was adequate.

We conclude that when undertaking bone studies with dietary interventions that include dairy, it is important to have a control diet that is free of casein or other milk-derived proteins. However, alternative protein sources may also confound experimental results because of the presence of other bone-active factors, such as soya protein containing isoflavones. Future work would be to directly compare the effect of dietary protein on bone mineralisation, using a broader range of proteins. Overall, this study showed that effects of vitamin D<sub>3</sub> deficiency in solid diets were reversed by offering milk supplemented with vitamin D<sub>3</sub>, and suggests that using milk as a vehicle to deliver vitamin D is advantageous.

### Acknowledgements

The authors thank Daralyn Hurford, Julie Cakebread, Ric Broadhurst and Anne Broomfield for their expert assistance in animal experiments and laboratory analyses, Harold Henderson for his expert assistance with the statistical analysis and Pauline Hunt for her expert presentation of the figures.

This work was supported by a grant from the New Zealand Ministry of Business, Innovation and Employment (Contract C10×1203). The Ministry had no role in the design, analysis or writing of this article. The Dairy Goat Co-operative (NZ) Ltd provided milk powders for the study.

The authors' contributions were as follows: A. J. H. and C. G. P. conceptualised and designed the study; O. A. M. W. conducted the experiments; A. J. H., C. P. and M. C. K. analysed and interpreted the data; A. J. H. wrote the first draft of the manuscript; and all authors critically reviewed the manuscript and approved the final content.

None of the authors has any conflicts of interest to declare

### References

1. Spiro A & Buttriss JL (2014) Vitamin D: an overview of vitamin D status and intake in Europe. *Nutr Bull* **39**, 322–350.
2. Calvo MS, Whiting SJ & Barton CN (2005) Vitamin D intake: a global perspective of current status. *J Nutr* **135**, 310–316.





3. Tripkovic L, Lambert H, Hart K, *et al.* (2012) Comparison of vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr* **95**, 1357–1364.
4. Haussler MR (1986) Vitamin D receptors: nature and function. *Annu Rev Nutr* **6**, 527–562.
5. Holick MF (2007) Vitamin D deficiency. *N Engl J Med* **357**, 266–281.
6. Holick MF, Binkley NC, Bischoff-Ferrari HA, *et al.* (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96**, 1911–1930.
7. Thacher TD & Clarke BL (2011) Vitamin D insufficiency. *Mayo Clin Proc* **86**, 50–60.
8. Maguire JL, Birken CS, Khovratovich M, *et al.* (2013) Modifiable determinants of serum 25-hydroxyvitamin D status in early childhood: opportunities for prevention. *JAMA Pediatrics* **167**, 230–235.
9. Laaksi IT, Ruohola JS, Ylikomi TJ, *et al.* (2006) Vitamin D fortification as public health policy: significant improvement in vitamin D status in young Finnish men. *Eur J Clin Nutr* **60**, 1035–1038.
10. Calvo MS & Whiting SJ (2013) Survey of current vitamin D food fortification practices in the United States and Canada. *J Steroid Biochem Mol Biol* **136**, 211–213.
11. Lee GJ, Birken CS, Parkin PC, *et al.* (2014) Consumption of non-cow's milk beverages and serum vitamin D levels in early childhood. *CMAJ* **186**, 1287–1293.
12. Fox MK, Condon E, Briefel RR, *et al.* (2010) Food consumption patterns of young preschoolers: are they starting off on the right path? *J Am Diet Assoc* **110**, S52–S59.
13. Goldbohm RA, Rubingh CM, Lanting CI, *et al.* (2016) Food consumption and nutrient intake by children aged 10 to 48 months attending day care in The Netherlands. *Nutrients* **8**, 428.
14. Vanderhout SM, Birken CS, Parkin PC, *et al.* (2016) Higher milk fat content is associated with higher 25-hydroxyvitamin D concentration in early childhood. *Appl Physiol Nutr Metab* **41**, 516–521.
15. Vanderhout SM, Birken CS, Parkin PC, *et al.* (2016) Relation between milk-fat percentage, vitamin D, and BMI z score in early childhood. *Am J Clin Nutr* **104**, 1657–1664.
16. Hunt JR, Hunt CD, Zito CA, *et al.* (2008) Calcium requirements of growing rats based on bone mass, structure, or biomechanical strength are similar. *J Nutr* **138**, 1462–1468.
17. Viguet-Carrin S, Hoppler M, Membrez Scalfio F, *et al.* (2014) Peak bone strength is influenced by calcium intake in growing rats. *Bone* **68**, 85–91.
18. McKinnon H, Kruger M, Prosser C, *et al.* (2010) The effect of formulated goats' milk on calcium bioavailability in male growing rats. *J Sci Food Agric* **90**, 112–116.
19. Li Y, Seifert MF, Lim SY, *et al.* (2010) Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats. *Br J Nutr* **104**, 674–685.
20. Anderson PH, Sawyer RK, May BK, *et al.* (2007) 25-Hydroxyvitamin D requirement for maintaining skeletal health utilising a Sprague-Dawley rat model. *J Steroid Biochem Mol Biol* **103**, 592–595.
21. Hohman EE, Martin BR, Lachcik PJ, *et al.* (2011) Bioavailability and efficacy of vitamin D<sub>2</sub> from UV-irradiated yeast in growing, vitamin D-deficient rats. *J Agric Food Chem* **59**, 2341–2346.
22. Lester GE, VanderWiel CJ, Gray TK, *et al.* (1982) Vitamin D deficiency in rats with normal serum calcium concentrations. *Proc Natl Acad Sci U S A* **79**, 4791–4794.
23. Anderson PH, Sawyer RK, Moore AJ, *et al.* (2008) Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. *J Bone Miner Res* **23**, 1789–1797.
24. Indyk H & Woollard DC (1985) The determination of vitamin D in fortified milk powders and infant formulas by HPLC. *J Micronutr Anal* **1**, 121–141.
25. Brubacher G, Muller-Mulot W & Southgate DAT (1986) *Methods for the Determination of Vitamins in Food: Recommended by COST 91*. London: Elsevier Science Publishers.
26. Lankes U, Elder PA, Lewis JG, *et al.* (2015) Differential extraction of endogenous and exogenous 25-OH-vitamin D from serum makes the accurate quantification in liquid chromatography-tandem mass spectrometry assays challenging. *Ann Clin Biochem* **52**, 151–160.
27. Hollander D, Muralidhara K & Zimmerman A (1978) Vitamin D-3 intestinal absorption *in vivo*: influence of fatty acids, bile salts, and perfusate pH on absorption. *Gut* **19**, 267–272.
28. Dawson-Hughes B, Harris SS, Palermo NJ, *et al.* (2013) Meal conditions affect the absorption of supplemental vitamin D<sub>3</sub> but not the plasma 25-hydroxyvitamin D response to supplementation. *J Bone Miner Res* **28**, 1778–1783.
29. Dawson-Hughes B, Harris SS, Lichtenstein AH, *et al.* (2015) Dietary fat increases vitamin D-3 absorption. *J Acad Nutr Diet* **115**, 225–230.
30. Tangpricha V, Koutkia P, Rieke SM, *et al.* (2003) Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. *Am J Clin Nutr* **77**, 1478–1483.
31. Sidnell A, Pigat S, Gibson S, *et al.* (2016) Nutrient intakes and iron and vitamin D status differ depending on main milk consumed by UK children aged 12–18 months—secondary analysis from the Diet and Nutrition Survey of Infants and Young Children. *J Nutr Sci* **5**, e32.
32. Houghton LA, Gray AR, Szymlek-Gay EA, *et al.* (2011) Vitamin D-fortified milk achieves the targeted serum 25-hydroxyvitamin D concentration without affecting that of parathyroid hormone in New Zealand toddlers. *J Nutr* **141**, 1840–1846.
33. Masarwi M, Gabet Y, Dolkart O, *et al.* (2016) Skeletal effect of casein and whey protein intake during catch-up growth in young male Sprague-Dawley rats. *Br J Nutr* **116**, 59–69.
34. Bozzini C, Champin GM, Alippi RM, *et al.* (2013) Static biomechanics in bone from growing rats exposed chronically to simulated high altitudes. *High Alt Med Biol* **14**, 367–374.
35. Arjmandi BH, Alekel L, Hollis BW, *et al.* (1996) Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. *J Nutr* **126**, 161.
36. Ghisolfi J, Fantino M, Turck D, *et al.* (2013) Nutrient intakes of children aged 1–2 years as a function of milk consumption, cows' milk or growing-up milk. *Public Health Nutr* **16**, 524–534.
37. Cai DJ, Zhao Y, Glasier J, *et al.* (2005) Comparative effect of soy protein, soy isoflavones, and 17 $\beta$ -estradiol on bone metabolism in adult ovariectomized rats. *J Bone Miner Res* **20**, 828–839.
38. Tsuchita H, Suzuki T & Kuwata T (2001) The effect of casein phosphopeptides on calcium absorption from calcium-fortified milk in growing rats. *Br J Nutr* **85**, 5–10.
39. Lee YS, Noguchi T & Naito H (1980) Phosphopeptides and soluble calcium in the small intestine of rats given a casein diet. *Br J Nutr* **43**, 457–467.
40. Bennett T, Desmond A, Harrington M, *et al.* (2000) The effect of high intakes of casein and casein phosphopeptide on calcium absorption in the rat. *Br J Nutr* **83**, 673–680.
41. Yuan YV & Kitts DD (1991) Confirmation of calcium absorption and femoral utilization in spontaneously hypertensive rats



- fed casein phosphopeptide supplemented diets. *Nutr Res* **11**, 1257–1272.
42. Adil S (2016) Insight into chicken egg proteins and their role in chemical defense mechanism. *Int J Poult Sci* **15**, 76–80.
  43. Wagner CL & Greer FR (2008) Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. *Pediatrics* **122**, 1142–1152.
  44. Bischoff-Ferrari HA, Willett WC, Wong JB, *et al.* (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. *Arch Intern Med* **169**, 551–561.
  45. Jones KS, Assar S, Harnpanich D, *et al.* (2014) 25(OH)D<sub>2</sub> half-life is shorter than 25(OH)D<sub>3</sub> half-life and is influenced by DBP concentration and genotype. *J Clin Endocrinol Metab* **99**, 3373–3381.